GE Healthcare has announced that the first integrated, simultaneous, time-of-flight (TOF) capable, whole body Signa PET/MR is 510(k) pending at the US Food and Drug Administration. Powered by simultaneous image acquisition from GE’s latest 3.0 Tesla magnetic resonance (MR) technology and innovative positron emission tomography (PET) technology, the Signa PET/MR represents a new chapter in helping clinicians achieve improved scan efficiency that may lead to more effective treatment paths for clinicians to offer their patients, particularly for oncology, neurology, and cardiology.
MR is excellent for imaging soft tissue as well as functional and morphological details. PET enables clinicians to visualise cellular activity and metabolism. When these two powerful tools are combined, clinicians may be able to see early cellular changes that can be accurately mapped onto MR images. With this knowledge, clinicians may be able to shorten the time between diagnosis and treatment, in addition to offering the convenience of simultaneous PET and MR scans for patients. Research systems are installed at Stanford University, University of California San Francisco, and University of Zurich.
“We are excited about Signa PET/MR because of its clinical and research potential,” says Andrei H Iagaru, associate professor of Radiology and co-chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford University Medical Center. “We have been using the system for research and we are able to explore novel things in areas like neurology and oncology, as well as in paediatrics in the future. Additionally, it is more convenient for the patient due to simultaneous scanning. We can also initiate innovative, complex research; simultaneity allows us to do functional neuro imaging, cardiac imaging, and musculoskeletal imaging that we haven’t been able to do before. Time-of-flight offers improved image quality in PET/MR and with the increased detector sensitivity, it may lead to future improvements in dose reduction.”
The Signa PET/MR features GE’s new, exclusive MR-compatible silicon photomultiplier detector (SiPM) technology. This new digital detector is characterised by its enhanced sensitivity; it is up to three times more sensitive than conventional PET technology. It also features fast coincidence timing resolution enabling TOF reconstruction. With TOF reconstruction, the arrival times of each coincident pair of photons are more precisely detected, and the time difference between them is used to localise the PET signal accurately. TOF leads to improved PET image quality with higher structural detail and improved signal-to-noise ratio. The Signa PET/MR is designed to be fully upgradable from a Discovery MR750w 3.0T.
“We have received extremely positive feedback from our installations of the research PET/MR systems,” says Richard Hausmann, president and chief executive officer of GE Healthcare MR. “Our research partners are very excited by the performance of the system and the potential of this new technology. We are proud to bring the first TOF-capable, simultaneous PET/MR system, pending FDA clearance, to market.”
Signa PET/MR is 510(k) pending at FDA. Not available for sale in the United States. Not yet CE marked. Not available for sale in all regions.